Florida Senate - 2012 COMMITTEE AMENDMENT
Bill No. SB 1506
Barcode 358292
LEGISLATIVE ACTION
Senate . House
Comm: WD .
02/09/2012 .
.
.
.
—————————————————————————————————————————————————————————————————
—————————————————————————————————————————————————————————————————
The Committee on Health Regulation (Garcia) recommended the
following:
1 Senate Substitute for Amendment (227268) (with title
2 amendment)
3
4 Delete everything after the enacting clause
5 and insert:
6 Section 1. Subsections (3), (4), and (5) of section
7 463.002, Florida Statutes, are amended to read:
8 463.002 Definitions.—As used in this chapter, the term:
9 (3)(a) “Licensed practitioner” means a person who is a
10 primary health care provider licensed to engage in the practice
11 of optometry under the authority of this chapter.
12 (b) A licensed practitioner who is not a certified
13 optometrist shall be required to display at her or his place of
14 practice a sign which states, “I am a Licensed Practitioner, not
15 a Certified Optometrist, and I am not able to prescribe topical
16 ocular pharmaceutical agents.”
17 (c) All practitioners initially licensed after July 1,
18 1993, must be certified optometrists.
19 (4) “Certified optometrist” means a licensed practitioner
20 authorized by the board to administer and prescribe topical
21 ocular pharmaceutical agents.
22 (5) “Optometry” means the diagnosis of conditions of the
23 human eye and its appendages; the employment of any objective or
24 subjective means or methods, including the administration of
25 topical ocular pharmaceutical agents, for the purpose of
26 determining the refractive powers of the human eyes, or any
27 visual, muscular, neurological, or anatomic anomalies of the
28 human eyes and their appendages; and the prescribing and
29 employment of lenses, prisms, frames, mountings, contact lenses,
30 orthoptic exercises, light frequencies, and any other means or
31 methods, including topical ocular pharmaceutical agents, for the
32 correction, remedy, or relief of any insufficiencies or abnormal
33 conditions of the human eyes and their appendages.
34 Section 2. Paragraph (g) of subsection (1) of section
35 463.005, Florida Statutes, is amended to read:
36 463.005 Authority of the board.—
37 (1) The Board of Optometry has authority to adopt rules
38 pursuant to ss. 120.536(1) and 120.54 to implement the
39 provisions of this chapter conferring duties upon it. Such rules
40 shall include, but not be limited to, rules relating to:
41 (g) Administration and prescription of topical ocular
42 pharmaceutical agents.
43 Section 3. Section 463.0055, Florida Statutes, is amended
44 to read:
45 463.0055 Administration and prescription of topical ocular
46 pharmaceutical agents; committee.—
47 (1)(a) Certified optometrists may administer and prescribe
48 topical ocular pharmaceutical agents as provided in this section
49 for the diagnosis and treatment of ocular conditions of the
50 human eye and its appendages without the use of surgery or other
51 invasive techniques. However, a licensed practitioner who is not
52 certified may use topically applied anesthetics solely for the
53 purpose of glaucoma examinations, but is otherwise prohibited
54 from administering or prescribing topical ocular pharmaceutical
55 agents.
56 (b) Before a certified optometrist may administer or
57 prescribe oral ocular pharmaceutical agents, the certified
58 optometrist must complete a course and subsequent examination on
59 general and ocular pharmacology which have a particular emphasis
60 on the ingestion of oral pharmaceutical agents and the side
61 effects of those agents. For certified optometrists licensed
62 before January 1, 1990, the course shall consist of 50 contact
63 hours and 25 of those hours shall be Internet-based. For
64 certified optometrists licensed on or after January 1, 1990, the
65 course shall consist of 20 contact hours and 10 of those hours
66 shall be Internet-based. The first course and examination shall
67 be presented by January 1, 2013, and shall thereafter be
68 administered at least annually. The Florida Medical Association
69 and the Florida Optometric Association shall jointly develop and
70 administer a course and examination for such purpose and jointly
71 determine the site or sites for the course and examination.
72 (2)(a) There is hereby created a committee composed of two
73 certified optometrists licensed pursuant to this chapter,
74 appointed by the Board of Optometry, two board-certified
75 ophthalmologists licensed pursuant to chapter 458 or chapter
76 459, appointed by the Board of Medicine, and one additional
77 person with a doctorate degree in pharmacology who is not
78 licensed pursuant to chapter 458, chapter 459, or this chapter,
79 appointed by the State Surgeon General. The committee shall
80 review requests for additions to, deletions from, or
81 modifications of a formulary of topical ocular pharmaceutical
82 agents for administration and prescription by certified
83 optometrists and shall provide to the board advisory opinions
84 and recommendations on such requests. The formulary of topical
85 ocular pharmaceutical agents shall consist of those topical
86 ocular pharmaceutical agents that are appropriate to treat and
87 diagnose ocular diseases and disorders and that which the
88 certified optometrist is qualified to use in the practice of
89 optometry. The board shall establish, add to, delete from, or
90 modify the formulary by rule. Notwithstanding any provision of
91 chapter 120 to the contrary, the formulary rule shall become
92 effective 60 days from the date it is filed with the Secretary
93 of State.
94 (b) The topical formulary may be added to, deleted from, or
95 modified according to the procedure described in paragraph (a).
96 Any person who requests an addition, deletion, or modification
97 of an authorized topical ocular pharmaceutical agent shall have
98 the burden of proof to show cause why such addition, deletion,
99 or modification should be made.
100 (c) The State Surgeon General shall have standing to
101 challenge any rule or proposed rule of the board pursuant to s.
102 120.56. In addition to challenges for any invalid exercise of
103 delegated legislative authority, the administrative law judge,
104 upon such a challenge by the State Surgeon General, may declare
105 all or part of a rule or proposed rule invalid if it:
106 1. Does not protect the public from any significant and
107 discernible harm or damages;
108 2. Unreasonably restricts competition or the availability
109 of professional services in the state or in a significant part
110 of the state; or
111 3. Unnecessarily increases the cost of professional
112 services without a corresponding or equivalent public benefit.
113
114 However, there shall not be created a presumption of the
115 existence of any of the conditions cited in this subsection in
116 the event that the rule or proposed rule is challenged.
117 (d) Upon adoption of the topical formulary required by this
118 section, and upon each addition, deletion, or modification to
119 the topical formulary, the board shall mail a copy of the
120 amended topical formulary to each certified optometrist and to
121 each pharmacy licensed by the state.
122 (3) In addition to the formulary of topical ocular
123 pharmaceutical agents in subsection (2), there is created a
124 statutory formulary of oral pharmaceutical agents, which include
125 the following agents:
126 (a) The following analgesics, or their generic or
127 therapeutic equivalents, which may not be administered or
128 prescribed for more than 72 hours without consultation with a
129 physician licensed under chapter 458 or chapter 459 who is
130 skilled in diseases of the eye:
131 1. Tramadol hydrochloride.
132 2. Acetaminophen 300 mg with No. 3 codeine phosphate 30 mg.
133 (b) The following antibiotics, or their generic or
134 therapeutic equivalents:
135 1. Amoxicillin.
136 2. Azithromycin.
137 3. Ciproflaxacin.
138 4. Dicloxacillin.
139 5. Doxycycline.
140 6. Keflex.
141 7. Minocycline.
142 (c) The following antivirals, or their generic or
143 therapeutic equivalents:
144 1. Acyclovir.
145 2. Famciclovir.
146 3. Valacyclovir.
147 (d) The following oral anti-glaucoma agents, or their
148 generic or therapeutic equivalents, which may not be
149 administered or prescribed for more than 72 hours without
150 consultation with a physician licensed under chapter 458 or
151 chapter 459 who is skilled in diseases of the eye:
152 1. Acetazolamide.
153 2. Methazolamide.
154
155 Any oral pharmaceutical agent that is listed in the statutory
156 formulary set forth in this subsection and that is subsequently
157 determined by the United States Food and Drug Administration to
158 be unsafe for administration or prescription shall be considered
159 to have been deleted from the formulary of oral pharmaceutical
160 agents. The oral pharmaceutical agents on the statutory
161 formulary set forth in this subsection may not otherwise be
162 deleted by the board, the department, or the State Surgeon
163 General.
164 (4)(3) A certified optometrist shall be issued a prescriber
165 number by the board. Any prescription written by a certified
166 optometrist for a topical ocular pharmaceutical agent pursuant
167 to this section shall have the prescriber number printed
168 thereon.
169 Section 4. Subsection (3) of section 463.0057, Florida
170 Statutes, is amended to read:
171 463.0057 Optometric faculty certificate.—
172 (3) The holder of a faculty certificate may engage in the
173 practice of optometry as permitted by this section, but may not
174 administer or prescribe topical ocular pharmaceutical agents
175 unless the certificateholder has satisfied the requirements of
176 ss. 463.0055(1)(b) and s. 463.006(1)(b)4. and 5.
177 Section 5. Subsections (2) and (3) of section 463.006,
178 Florida Statutes, are amended to read:
179 463.006 Licensure and certification by examination.—
180 (2) The examination shall consist of the appropriate
181 subjects, including applicable state laws and rules and general
182 and ocular pharmacology with emphasis on the use topical
183 application and side effects of ocular pharmaceutical agents.
184 The board may by rule substitute a national examination as part
185 or all of the examination and may by rule offer a practical
186 examination in addition to the written examination.
187 (3) Each applicant who successfully passes the examination
188 and otherwise meets the requirements of this chapter is entitled
189 to be licensed as a practitioner and to be certified to
190 administer and prescribe topical ocular pharmaceutical agents in
191 the diagnosis and treatment of ocular conditions.
192 Section 6. Subsections (1) and (2) of section 463.0135,
193 Florida Statutes, are amended, and subsection (10) is added to
194 that section, to read:
195 463.0135 Standards of practice.—
196 (1) A licensed practitioner shall provide that degree of
197 care which conforms to that level of care provided by medical
198 practitioners in the same or similar communities. A certified
199 optometrist shall administer and prescribe oral ocular
200 pharmaceutical agents in a manner consistent with applicable
201 preferred practice patterns of the American Academy of
202 Ophthalmology. A licensed practitioner shall advise or assist
203 her or his patient in obtaining further care when the service of
204 another health care practitioner is required.
205 (2) A licensed practitioner diagnosing angle closure,
206 neovascular, infantile, or congenital forms of glaucoma shall
207 promptly and without unreasonable delay refer the patient to a
208 physician skilled in diseases of the eye and licensed under
209 chapter 458 or chapter 459. In addition, a licensed practitioner
210 shall timely refer any patient who experiences progressive
211 glaucoma due to failed pharmaceutical intervention to a
212 physician who is skilled in diseases of the eye and licensed
213 under chapter 458 or chapter 459.
214 (10) Comanagement of postoperative care shall be conducted
215 pursuant to an established protocol that governs the
216 relationship between the operating surgeon and the optometrist.
217 The patient shall be informed that either physician will be
218 available for emergency care throughout the postoperative
219 period, and the patient shall consent in writing to the
220 comanagement relationship.
221 Section 7. Subsections (3) and (4) of section 463.014,
222 Florida Statutes, are amended to read:
223 463.014 Certain acts prohibited.—
224 (3) Prescribing, ordering, dispensing, administering,
225 supplying, selling, or giving any systemic drugs for the purpose
226 of treating a systemic disease by a licensed practitioner is
227 prohibited. However, a certified optometrist is permitted to use
228 commonly accepted means or methods to immediately address
229 incidents of anaphylaxis.
230 (4) Surgery of any kind, including the use of lasers, is
231 expressly prohibited. For purposes of this subsection, the term
232 “surgery” means a procedure using an instrument, including
233 lasers, scalpels, or needles, in which human tissue is cut,
234 burned, or vaporized by incision, injection, ultrasound, laser,
235 or radiation. The term includes procedures using instruments
236 that require closing by suturing, clamping, or another such
237 device. Certified optometrists may remove superficial foreign
238 bodies. For the purposes of this subsection, the term
239 “superficial foreign bodies” means any foreign matter that is
240 embedded in the conjunctiva or cornea but which has not
241 penetrated the globe.
242 Section 8. Section 463.0141, Florida Statutes, is created
243 to read:
244 463.0141 Reports of adverse incidents in the practice of
245 optometry.—
246 (1) Any adverse incident that occurs on or after January 1,
247 2013, in the practice of optometry must be reported to the
248 department in accordance with this section.
249 (2) The required notification to the department must be
250 submitted in writing by certified mail and postmarked within 15
251 days after the occurrence of the adverse incident.
252 (3) For purposes of notification to the department, the
253 term “adverse incident,” as used in this section, means an event
254 that is associated in whole or in part with the prescribing of
255 an oral ocular pharmaceutical agent and that results in one of
256 the following:
257 (a) Any condition that requires the transfer of a patient
258 to a hospital licensed under chapter 395;
259 (b) Any condition that requires the patient to obtain care
260 from a physician licensed under chapter 458 or chapter 459,
261 other than a referral or a consultation required under this
262 chapter;
263 (c) Permanent physical injury to the patient;
264 (d) Partial or complete permanent loss of sight by the
265 patient; or
266 (e) Death of the patient.
267 (4) The department shall review each incident and determine
268 whether it potentially involved conduct by the licensed
269 practitioner which may be subject to disciplinary action, in
270 which case s. 456.073 applies. Disciplinary action, if any,
271 shall be taken by the board.
272 Section 9. Subsection (1) of section 483.035, Florida
273 Statutes, is amended to read:
274 483.035 Clinical laboratories operated by practitioners for
275 exclusive use; licensure and regulation.—
276 (1) A clinical laboratory operated by one or more
277 practitioners licensed under chapter 458, chapter 459, chapter
278 460, chapter 461, chapter 462, chapter 463, or chapter 466,
279 exclusively in connection with the diagnosis and treatment of
280 their own patients, must be licensed under this part and must
281 comply with the provisions of this part, except that the agency
282 shall adopt rules for staffing, for personnel, including
283 education and training of personnel, for proficiency testing,
284 and for construction standards relating to the licensure and
285 operation of the laboratory based upon and not exceeding the
286 same standards contained in the federal Clinical Laboratory
287 Improvement Amendments of 1988 and the federal regulations
288 adopted thereunder.
289 Section 10. Subsection (7) of section 483.041, Florida
290 Statutes, is amended to read:
291 483.041 Definitions.—As used in this part, the term:
292 (7) “Licensed practitioner” means a physician licensed
293 under chapter 458, chapter 459, chapter 460, or chapter 461, or
294 chapter 463; a dentist licensed under chapter 466; a person
295 licensed under chapter 462; or an advanced registered nurse
296 practitioner licensed under part I of chapter 464; or a duly
297 licensed practitioner from another state licensed under similar
298 statutes who orders examinations on materials or specimens for
299 nonresidents of the State of Florida, but who reside in the same
300 state as the requesting licensed practitioner.
301 Section 11. Subsection (5) of section 483.181, Florida
302 Statutes, is amended to read:
303 483.181 Acceptance, collection, identification, and
304 examination of specimens.—
305 (5) A clinical laboratory licensed under this part must
306 accept a human specimen submitted for examination by a
307 practitioner licensed under chapter 458, chapter 459, chapter
308 460, chapter 461, chapter 462, chapter 463, s. 464.012, or
309 chapter 466, if the specimen and test are the type performed by
310 the clinical laboratory. A clinical laboratory may only refuse a
311 specimen based upon a history of nonpayment for services by the
312 practitioner. A clinical laboratory shall not charge different
313 prices for tests based upon the chapter under which a
314 practitioner submitting a specimen for testing is licensed.
315 Section 12. Paragraph (b) of subsection (6) of section
316 766.106, Florida Statutes, is amended to read:
317 766.106 Notice before filing action for medical negligence;
318 presuit screening period; offers for admission of liability and
319 for arbitration; informal discovery; review.—
320 (6) INFORMAL DISCOVERY.—
321 (b) Informal discovery may be used by a party to obtain
322 unsworn statements, the production of documents or things, and
323 physical and mental examinations, and ex parte interviews, as
324 follows:
325 1. Unsworn statements.—Any party may require other parties
326 to appear for the taking of an unsworn statement. Such
327 statements may be used only for the purpose of presuit screening
328 and are not discoverable or admissible in any civil action for
329 any purpose by any party. A party desiring to take the unsworn
330 statement of any party must give reasonable notice in writing to
331 all parties. The notice must state the time and place for taking
332 the statement and the name and address of the party to be
333 examined. Unless otherwise impractical, the examination of any
334 party must be done at the same time by all other parties. Any
335 party may be represented by counsel at the taking of an unsworn
336 statement. An unsworn statement may be recorded electronically,
337 stenographically, or on videotape. The taking of unsworn
338 statements is subject to the provisions of the Florida Rules of
339 Civil Procedure and may be terminated for abuses.
340 2. Documents or things.—Any party may request discovery of
341 documents or things. The documents or things must be produced,
342 at the expense of the requesting party, within 20 days after the
343 date of receipt of the request. A party is required to produce
344 discoverable documents or things within that party’s possession
345 or control. Medical records shall be produced as provided in s.
346 766.204.
347 3. Physical and mental examinations.—A prospective
348 defendant may require an injured claimant to appear for
349 examination by an appropriate health care provider. The
350 prospective defendant shall give reasonable notice in writing to
351 all parties as to the time and place for examination. Unless
352 otherwise impractical, a claimant is required to submit to only
353 one examination on behalf of all potential defendants. The
354 practicality of a single examination must be determined by the
355 nature of the claimant’s condition, as it relates to the
356 liability of each prospective defendant. Such examination report
357 is available to the parties and their attorneys upon payment of
358 the reasonable cost of reproduction and may be used only for the
359 purpose of presuit screening. Otherwise, such examination report
360 is confidential and exempt from the provisions of s. 119.07(1)
361 and s. 24(a), Art. I of the State Constitution.
362 4. Written questions.—Any party may request answers to
363 written questions, the number of which may not exceed 30,
364 including subparts. A response must be made within 20 days after
365 receipt of the questions.
366 5. Unsworn statements of treating health care providers.—A
367 prospective defendant or his or her legal representative may
368 also take unsworn statements of the claimant’s treating health
369 care providers. The statements must be limited to those areas
370 that are potentially relevant to the claim of personal injury or
371 wrongful death. Subject to the procedural requirements of
372 subparagraph 1., a prospective defendant may take unsworn
373 statements from a claimant’s treating physicians. Reasonable
374 notice and opportunity to be heard must be given to the claimant
375 or the claimant’s legal representative before taking unsworn
376 statements. The claimant or claimant’s legal representative has
377 the right to attend the taking of such unsworn statements.
378 6. Ex parte interviews of treating health care providers.—A
379 prospective defendant or his or her legal representative may
380 interview the claimant’s treating health care providers without
381 the presence of the claimant or the claimant’s legal
382 representative. If a prospective defendant or his or her legal
383 representative intends to interview a claimant’s health care
384 providers, the prospective defendant must provide the claimant
385 with notice of such interview at least 10 days before the date
386 of the interview.
387 Section 13. Section 766.1091, Florida Statutes, is created
388 to read:
389 766.1091 Voluntary binding arbitration; damages.—
390 (1) A health care provider licensed under chapter 458,
391 chapter 459, chapter 463, or chapter 466; any entity owned in
392 whole or in part by a health care provider licensed under
393 chapter 458, chapter 459, chapter 463, or chapter 466; or any
394 health care clinic licensed under part X of chapter 400, and a
395 patient or prospective patient, may agree in writing to submit
396 to arbitration any claim for medical negligence which may
397 currently exist or may accrue in the future and would otherwise
398 be brought pursuant to this chapter. Any arbitration agreement
399 entered into pursuant to this section shall be governed by
400 chapter 682.
401 (2) Any arbitration agreement entered into pursuant to
402 subsection (1) may contain a provision that limits the available
403 damages in an arbitration award.
404 Section 14. Subsection (21) of section 893.02, Florida
405 Statutes, is amended to read:
406 893.02 Definitions.—The following words and phrases as used
407 in this chapter shall have the following meanings, unless the
408 context otherwise requires:
409 (21) “Practitioner” means a physician licensed pursuant to
410 chapter 458, a dentist licensed pursuant to chapter 466, a
411 veterinarian licensed pursuant to chapter 474, an osteopathic
412 physician licensed pursuant to chapter 459, a naturopath
413 licensed pursuant to chapter 462, a certified optometrist
414 licensed under chapter 463, or a podiatric physician licensed
415 pursuant to chapter 461, provided such practitioner holds a
416 valid federal controlled substance registry number.
417 Section 15. Subsection (1) of section 893.05, Florida
418 Statutes, is amended to read:
419 893.05 Practitioners and persons administering controlled
420 substances in their absence.—
421 (1) A practitioner, in good faith and in the course of his
422 or her professional practice only, may prescribe, administer,
423 dispense, mix, or otherwise prepare a controlled substance, or
424 the practitioner may cause the same to be administered by a
425 licensed nurse or an intern practitioner under his or her
426 direction and supervision only. A veterinarian may so prescribe,
427 administer, dispense, mix, or prepare a controlled substance for
428 use on animals only, and may cause it to be administered by an
429 assistant or orderly under the veterinarian’s direction and
430 supervision only. A certified optometrist licensed under chapter
431 463 may not administer or prescribe pharmaceutical agents in
432 Schedule I or Schedule II of the Florida Comprehensive Drug
433 Abuse Prevention and Control Act.
434 Section 16. This act shall take effect July 1, 2012.
435
436
437 ================= T I T L E A M E N D M E N T ================
438 And the title is amended as follows:
439 Delete everything before the enacting clause
440 and insert:
441 A bill to be entitled
442 An act relating to health care; amending s. 463.002,
443 F.S.; conforming provisions to changes made by the
444 act; amending s. 463.005, F.S.; authorizing the Board
445 of Optometry to adopt rules for the administration and
446 prescription of ocular pharmaceutical agents; amending
447 s. 463.0055, F.S.; authorizing certified optometrists
448 to administer and prescribe pharmaceutical agents
449 under certain circumstances; requiring that a
450 certified optometrist complete a course and subsequent
451 examination on general and ocular pharmacology;
452 providing requirements for the course; requiring that
453 the Florida Medical Association and the Florida
454 Optometric Association jointly develop and administer
455 the course and examination; revising qualifications of
456 certain members of the formulary committee; providing
457 for a formulary of topical ocular pharmaceutical
458 agents which the committee may modify; specifying the
459 agents that make up the statutory formulary of oral
460 pharmaceutical agents; authorizing the deletion of an
461 oral pharmaceutical agent listed in the statutory
462 formulary under certain circumstances; prohibiting the
463 board, the Department of Health, or the State Surgeon
464 General from deleting an oral pharmaceutical agent
465 listed in the statutory formulary; amending ss.
466 463.0057 and 463.006, F.S.; conforming provisions to
467 changes made by the act; amending s. 463.0135, F.S.;
468 requiring that a certified optometrist administer and
469 prescribe oral ocular pharmaceutical agents in a
470 certain manner; requiring that a licensed practitioner
471 who diagnoses a patient who has a neovascular form of
472 glaucoma or progressive glaucoma immediately refer the
473 patient to a physician who is skilled in the diseases
474 of the eye; requiring that comanagement of
475 postoperative care be conducted pursuant to an
476 established protocol; requiring that the patient be
477 informed that a physician will be available for
478 emergency care throughout the postoperative period;
479 requiring that the patient consent in writing to the
480 comanagement relationship; amending s. 463.014, F.S.;
481 revising certain prohibited acts regarding an
482 optometrist conducting surgery and dispensing,
483 administering, ordering, supplying, or selling certain
484 drugs; creating s. 463.0141, F.S.; requiring that
485 adverse incidents in the practice of optometry be
486 reported to the Department of Health; providing
487 requirements for notifying the department of an
488 adverse incident; providing a definition; requiring
489 that the department review each incident and determine
490 whether it involved conduct that is subject to
491 disciplinary action; requiring that the Board of
492 Optometry take disciplinary action if necessary;
493 amending s. 483.035, F.S., relating to licensure and
494 regulation of clinical laboratories operated by
495 practitioners for exclusive use; providing
496 applicability to clinical laboratories operated by
497 practitioners licensed to practice optometry; amending
498 s. 483.041, F.S.; revising the definition of the term
499 “licensed practitioner” to include a practitioner
500 licensed under ch. 463, F.S.; amending s. 483.181,
501 F.S.; requiring clinical laboratories to accept human
502 specimens submitted by practitioners licensed to
503 practice under ch. 463, F.S.; amending s. 766.106,
504 F.S.; authorizing a prospective defendant to obtain
505 informal discovery by conducting ex parte interviews
506 of treating health care providers; requiring advance
507 notice to the claimant of an ex parte interview;
508 creating s. 766.1091, F.S.; authorizing a health care
509 provider or health care clinic and a patient or
510 prospective patient to agree to submit a current or
511 future claim of medical negligence to arbitration;
512 requiring that the arbitration agreement be governed
513 by ch. 682, F.S.; authorizing the arbitration
514 agreement to contain a provision that limits an award
515 of damages; amending s. 893.02, F.S.; revising the
516 definition of the term “practitioner” to include
517 certified optometrists for purposes of the Florida
518 Comprehensive Drug Abuse Prevention and Control Act;
519 amending s. 893.05, F.S.; prohibiting certified
520 optometrists from administering and prescribing
521 certain controlled substances; providing an effective
522 date.